Gene Editing | Search Results | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Search Results for 'Gene Editing'

NEW GENRE Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology – Series B, Volume 2

Posted in on June 20, 2022|

View on Amazon.com https://www.amazon.com/dp/B0BQH14CSF Audio y Texto New Genre Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-two-latest-in-genomics-methodologies-for-therapeutics-gene-editing-ngs-and-bioinformatics-simulations-and-the-genome-ontology-series-b-volume-2/ Original Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology New Genre Volume Two: Latest in […]

Read Full Post »

CRISPR-Cas9 and the Power of Butterfly Gene Editing

Posted in Behavioral Genetics, CRISPR alternative for editing genes without cutting, CRISPR/Cas9 & Gene Editing, Genome Biology, Microbiologial genetics, Transcriptomics on August 23, 2020| Leave a Comment »

CRISPR-Cas9 and the Power of Butterfly Gene Editing Reporter: Madison Davis Genome editing is a relatively new branch of genetic engineering that utilizes modern technologies in altering, inserting, or deleting selective DNA sequences within cells. CRISPR-Cas9, otherwise known as “Clustered Regularly Interspaced Short Palindromic Repeat”, is a groundbreaking genome editing technique for scientists, as it […]

Read Full Post »

Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates

Posted in Alzheimer's Disease, Biomarkers & Medical Diagnostics, Cerebrovascular and Neurodegenerative Diseases, CRISPR alternative for editing genes without cutting, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Etiology, Gene Therapy & Gene Editing Development, Genome Biology, Genomic Expression, Neurodegenerative Diseases, Open Access Journals, RNA Biology, Scientific Publishing, tagged Alternate splicing, Chronic renal disease, CRISPR-Cas9, gene therapy, Huntington's disease, Spinal muscular atrophy on August 7, 2021| Leave a Comment »

Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates Reporter: Amandeep Kaur, BSc., MSc. Using viral vectors, lipid nanoparticles, and other technologies, significant progress has been achieved in refining the delivery of gene treatments. However, modifications to the cargo itself are still needed to increase safety and efficacy by better controlling gene expression. […]

Read Full Post »

Cancer treatment using CRISPR-based Genome Editing System

Posted in CRISPR/Cas9 & Gene Editing, Gene Therapy & Gene Editing Development, Genome Biology, tagged cancer metastasis, CRISPR-Cas9, CRISPR-LNP, gene editing on January 9, 2021| Leave a Comment »

Cancer treatment using CRISPR-based Genome Editing System Reporter: Irina Robu, PhD CRISPR, stands for “clusters of regularly interspaced short palindromic repeats” is one of the biggest accomplishments in science of this decade and it is the simplest tool for altering DNA sequences and modifying gene functions. The technology is adapted form the natural defense mechanism […]

Read Full Post »

Explanation on “Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP” on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C

Posted in Machine Learning, Natural Language Processing (NLP) on July 7, 2022| Leave a Comment »

Explanation on “Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP” on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C NEW GENRE Edition, Editor-in-Chief: Aviva Lev-Ari, PhD, RN Series B: Frontiers in […]

Read Full Post »

NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research

Posted in on June 5, 2022|

Series B: Frontiers in Genomics Research NEW GENRE Audio English-Spanish View on Amazon.com Spanish Series B Fronteras de la investigación genómica (3 book series) Kindle Edition by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala […]

Read Full Post »

The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna

Posted in Award Nominations, Cell Biology, CRISPR alternative for editing genes without cutting, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, DNA repair, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Interviews with Key Opinion Leaders (KOLs), Molecular Genetics & Pharmaceutical, Nobel Prize WInners, Stem Cells for Regenerative Medicine, tagged CRISPR –Cas9 system for genetic engineering, CRISPR Biology • Genome Editing • Gene Drives • DNA Repair • Model and Industrial Organisms • Technology Development • Stem Cells/Cancer • Genome-Wide Screens, CRISPR-based gene editing, CRISPR-Cas9, CRISPR/Cas and base editing, gene editing, gene editing technology platform, Jennifer Doudna, nobel leureates, Nobel Prize, Nobel Prize in Chemistry, Stanford University on October 8, 2020| Leave a Comment »

The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna Reporters: Stephen J. Williams, Ph.D. and Aviva Lev-Ari, PhD, RN The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to Emmanuelle CharpentierMax Planck Unit for the Science of Pathogens, Berlin, Germany Jennifer A. DoudnaUniversity of California, Berkeley, […]

Read Full Post »

Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility

Posted in CAR-T, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Disease Biology, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genome Biology, tagged Broad Institute, CRISPR, CRISPR –Cas9 system for genetic engineering, CRISPR-based gene editing, Editas, gene editing technology platform, genetic engineering, Nature, off target effects, Tay-Sachs on August 29, 2020| Leave a Comment »

Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility Reporter: Stephen J. Williams, PhD CRISPR has become a powerful molecular for the editing of genomes tool in research, drug discovery, and the clinic (see posts and ebook on this site below) Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene […]

Read Full Post »

Genetic variation causes human lupus, systemic lupus erythematosus (SLE)

Posted in Autoimmune Inflammatory DIseases, CRISPR/Cas9 & Gene Editing, Genome Biology, Genomic Endocrinology, Inflammatory Pathophysiology, RNA Biology, Signaling & Cell Circuits, Single Cell Genomics, Single-cell sequencing, Systemic Inflammatory Response Related Disorders, Variation in human protein-coding regions on February 23, 2023| Leave a Comment »

Genetic variation causes human lupus, systemic lupus erythematosus (SLE) Reporter: Aviva Lev-Ari, PhD, RN TLR7 gain-of-function genetic variation causes human lupus Abstract Although circumstantial evidence supports enhanced Toll-like receptor 7 (TLR7) signalling as a mechanism of human systemic autoimmune disease1,2,3,4,5,6,7, evidence of lupus-causing TLR7 gene variants is lacking. Here we describe human systemic lupus erythematosus caused by […]